Revenue Showdown: Teva Pharmaceutical Industries Limited vs Ligand Pharmaceuticals Incorporated

Pharma Revenue Trends: Teva vs. Ligand

__timestampLigand Pharmaceuticals IncorporatedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20146453800020272000000
Thursday, January 1, 20157191400019652000000
Friday, January 1, 201610897300021903000000
Sunday, January 1, 201714110200022385000000
Monday, January 1, 201825145300018854000000
Tuesday, January 1, 201912028200016887000000
Wednesday, January 1, 202018641900016658000000
Friday, January 1, 202127713300015878000000
Saturday, January 1, 202219624500014925000000
Sunday, January 1, 202313131400015846000000
Monday, January 1, 202416544000000
Loading chart...

Igniting the spark of knowledge

Revenue Trends in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical industry, revenue trends offer a glimpse into the financial health and market positioning of companies. Over the past decade, Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated have showcased contrasting revenue trajectories. From 2014 to 2023, Teva's revenue has seen a decline of approximately 22%, dropping from its peak in 2017. This trend reflects the challenges faced by the company in a competitive market.

Conversely, Ligand Pharmaceuticals has experienced a remarkable growth of nearly 104% in the same period, peaking in 2021. This growth underscores Ligand's strategic positioning and innovative approaches in the pharmaceutical sector. The data highlights the dynamic nature of the industry, where adaptability and innovation are key to sustaining growth. As the pharmaceutical landscape continues to shift, these trends provide valuable insights for investors and industry stakeholders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025